Zoetis Inc (NYSE:ZTS) Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL reduced its stake in Zoetis Inc (NYSE:ZTS) by 8.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 187,100 shares of the company’s stock after selling 16,320 shares during the period. Gamco Investors INC. ET AL’s holdings in Zoetis were worth $21,234,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of ZTS. Forbes J M & Co. LLP raised its holdings in shares of Zoetis by 11.1% during the second quarter. Forbes J M & Co. LLP now owns 146,325 shares of the company’s stock valued at $16,606,000 after acquiring an additional 14,567 shares during the period. Clarius Group LLC grew its position in Zoetis by 110.3% in the second quarter. Clarius Group LLC now owns 5,863 shares of the company’s stock worth $665,000 after acquiring an additional 3,075 shares in the last quarter. Jacobsen Capital Management bought a new stake in Zoetis in the second quarter worth approximately $692,000. Comerica Bank grew its position in Zoetis by 33.4% in the second quarter. Comerica Bank now owns 294,510 shares of the company’s stock worth $33,480,000 after acquiring an additional 73,689 shares in the last quarter. Finally, Next Capital Management LLC grew its position in Zoetis by 156.5% in the second quarter. Next Capital Management LLC now owns 295 shares of the company’s stock worth $33,000 after acquiring an additional 180 shares in the last quarter. 90.42% of the stock is owned by institutional investors.

Several analysts recently issued reports on ZTS shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price objective (up from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. BMO Capital Markets upped their price objective on shares of Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a report on Thursday, May 9th. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Monday, May 6th. SunTrust Banks upped their price objective on shares of Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a report on Tuesday, August 13th. Finally, Gabelli downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price objective for the company. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Zoetis currently has an average rating of “Buy” and a consensus target price of $115.13.

Zoetis stock traded up $1.13 during mid-day trading on Monday, reaching $126.50. The company had a trading volume of 185,316 shares, compared to its average volume of 2,032,774. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74. Zoetis Inc has a 52 week low of $78.90 and a 52 week high of $125.88. The company has a 50 day moving average of $116.54 and a 200-day moving average of $104.33. The firm has a market cap of $59.06 billion, a price-to-earnings ratio of 40.42, a PEG ratio of 3.12 and a beta of 0.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same quarter in the prior year, the company posted $0.77 EPS. The business’s revenue was up 9.3% on a year-over-year basis. On average, analysts predict that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.

In other news, Director Willie M. Reed sold 1,900 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $110.58, for a total value of $210,102.00. Following the completion of the transaction, the director now owns 2,816 shares in the company, valued at approximately $311,393.28. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Roman Trawicki sold 4,700 shares of the stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $109.00, for a total transaction of $512,300.00. Following the sale, the insider now owns 2,199 shares of the company’s stock, valued at approximately $239,691. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,969 shares of company stock valued at $4,520,953. Corporate insiders own 0.29% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: CD Ladder

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.